Post-operative radiotherapy for ductal carcinoma in situ of the breast

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 11, 2013, Pages

  Goodwin, Annabel ^a   Parker, Sharon ^b   Ghersi, Davina ^c   Wilcken, Nicholas ^d  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; TUMOR INVASION; BREAST TUMOR; CARCINOMA IN SITU; META ANALYSIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEGMENTAL MASTECTOMY;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84900786469     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000563.pub7     Document Type: Review

References (41)

1. Bijker N, Meijnen P, Peterse J, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853, a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Journal of Clinical Oncology 2006;24(21):3381-7.
2. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853. Journal of Clinical Oncology 2001;19(8):2263-71.
3. Bijker N, Peterse JL, Fentiman IS, Julien JP, Hart AAM, Avril A, et al. Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. British Journal of Cancer 2002;87:615-20.
4. Bijker N, Rutgers EJT, Peterse JL, Fentiman IS, Julien JP, Duchateau L, et al. Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. European Journal of Surgical Oncology 2001;27:135-40.
5. Fentiman IS, Julien JP, Mignolet F. EORTC trial 10853: treatment options for completely excised ductal carcinoma of the breast. European Journal of Surgical Oncology 1993;19:499.
6. Fentiman IS, Julien JP, van Dongen JA, van Geel B, Chetty U, Coibion M. Reasons for non-entry of patients with DCIS of the breast into a randomised trial (EORTC 10853). European Journal of Cancer 1991;27(4):450-52.
7. Julien JP, Biijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. Lancet 2000;355:529-33.
8. Fisher B, Dignam J, Wolmark N, Mamounas E, Constantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings form the National Surgical Adjuvant Breast and Bowel Project B-17. Journal of Clinical Oncology 1993;16(2):441-52.
9. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraduct breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B17. Journal of Clinical Oncology 1998;16(2):441-52.
10. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Seminars in Oncology 2001;28(4):400-18.
11. Fisher ER, Costantino J, Fisher B, Palekar A S, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B17. Cancer 1995;75(6):1310-9.
12. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight year update of Protocol B17. Cancer 1999;86(3):429-38.
13. NoÎl G, Proudhom MA, Mazeron JJ. [Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17]. Cancer Radiothèrapie: Journal de la Sociètè Française de Radiothèrapie Oncologique 1999;3(4):342-3.
14. Emdin SO, Granstrand B, Ringberg AR, Sandelin K, Arnesson L-G, Nordgren H, et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncologica 2006;45:536-43.
15. Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson L-G, Sandelin K, et al. Absolute risk reductions for local recurrence after post operative radiotherapy after sector resection for ductal carcinoma in situ. Journal of Clinical Oncology 2008;26(8):1247-52.
16. Ringberg A, Nordgren H, Thorstensson S, Idvall I, Garmo H, Granstrand B, et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast - Results from the Swedish randomised trial. European Journal of Cancer 2007;43:291-8.
17. George WD, Houghton J, Cuzick J, Forbes J. Radiotherapy and tamoxifen following complete local excision (CLE) in the management of ductal carcinoma in situ (DCIS): Preliminary results from the UK DCIS trial. Proceedings of the American Society of Clinical Oncology. 2000; Vol. Abstract No 270.
18. Stewart HJ. The UKCCCR treatment trial in localised DCIS of the breast [abstract]. British Journal of Cancer 1990 Suppl XII;62:34.
19. UK Coordinating Committee on Cancer Research (UKCCCR). Radiotherapy and tamoxifen in women with completely excised carcinoma in situ of the breast in the UK, Australia and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
20. Assersohn L, Powles TJ, Ashley S, Nash AG, Neal AJ, Sacks N, et al. Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. Annals of Oncology 1999;10(12):1451-5.
21. Clark RM, McCulloch PB, Levine MN, Lipa M, Wilkinson RH, Mahoney LJ, et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. Journal of the National Cancer Institute 1992;84(9):683-9.
22. Goel V, Olivotto I, Hislop TG, Sawka C, Coldman A, Holowaty EJ. Patterns of initial management of node-negative breast cancer in two Canadian provinces. British Columbia/Ontario Working Group. Canadian Medical Association Journal 1997;156:25-35.
23. Lee RPF, Vincenti A, Buchanan R, Rainsbury RM. Selective radiotherapy following wide local excision of breast cancer: Early results of a randomized trial (abstract). European Journal of Cancer 1994;30 Suppl 2:42.
24. Polgar C, Orosz Z, Kahan Z, Gabor G, Jani N, Csemi G, et al. Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study [Hungarian]. Magyar Onkologia 2008;52(3):269-77.
25. Silverstein MJ, Waisman JR, Gierson ED, Colburn W, Gamagami P, Lewinsky BS. Radiation therapy for intraductal carcinoma. Is it an equal alternative?. Archives of surgery 1991;126(4):424-8.
26. Adjuvant radiation therapy compared with observation after surgery in treating women with estrogen receptor positive or progesterone receptor positive ductal carcinoma In situ of the breast who are receiving tamoxifen or anastrozole. Ongoing study February 2004.
27. Phase III trial of observation +/- tamoxifen versus RT +/- tamoxifen for good risk ductal carcinoma in situ (DCIS) of the female breast. Ongoing study December 1999.
28. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. New England Journal of Medicine 2004;350:1430-41.
29. Higgins JPT, Green S (editors). The Cochrane Collaboration, 2008. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. Th Cochrane Collaboration, Updated February 2008.
30. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 2000;9217(355):1757-70.
31. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (second of three parts). New England Journal of Medicine 1992;327(6):390-8.
32. Levine M. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). Canadian Medical Association Journal 2001;165(7):912-3.
33. Millikan R, Dressler L, Geradts J, Graham M. The need for epidemiologic studies of in-situ carcinoma of the breast. Breast Cancer Research and Treatment 1995;35:65-77.
34. Mokbel K. Towards optimal management of ductal carcinoma in situ of the breast. European Journal of Surgical Oncology 2002;29:191-7.
35. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Harris JR, et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). A Cancer Journal for Clinicians 2002;52(5):256-76.
36. National Breast Cancer Centre. The clinical management of ductal carcinoma in situ, lobular carcinoma in situ and atypical hyperplasia of the breast. 1. National Breast Cancer Centre, 2003.
37. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
38. Reaby L. The quality and coping patterns of women's decision-making regarding breast cancer surgery. Psycho-Oncology 1998;7:252-62.
39. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
40. Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron PJ, et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. Journal of Clinical Oncology 1998;16:1367-73.
41. Solin LJ, Fourquet A, Vicini FA, Haffty B, Taylor M, McCormick B, et al. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast. Cancer 2001;91:1090-7.